Literature DB >> 14755014

Diagnosis and treatment of cholangiocarcinoma.

Christopher D Anderson1, C Wright Pinson, Jordan Berlin, Ravi S Chari.   

Abstract

Cholangiocarcinoma presents a formidable diagnostic and treatment challenge. The majority of patients present with unresectable disease and have a survival of less than 12 months following diagnosis. Progress has been made by the appropriate selection of patients for treatment options including resection, with the routine use of more aggressive resections in order to achieve margin-negative resections. This has resulted in longer survival times for these patients. Neoadjuvant and adjuvant therapies have, for the most part, not improved survival in patients with this tumor, and new strategies are needed to improve this line of therapy. The prognosis for unresectable patients is poor, and palliative measures should be aimed at increasing quality of life first and increasing survival second.

Entities:  

Mesh:

Year:  2004        PMID: 14755014     DOI: 10.1634/theoncologist.9-1-43

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  117 in total

Review 1.  Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

Authors:  J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó
Journal:  Aliment Pharmacol Ther       Date:  2011-09-20       Impact factor: 8.171

2.  Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis.

Authors:  M Giovannini; E Bories; G Monges; C Pesenti; F Caillol; J R Delpero
Journal:  Surg Endosc       Date:  2011-03-18       Impact factor: 4.584

Review 3.  Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.

Authors:  Lynn Jeanette Savic; Julius Chapiro; Jean-François H Geschwind
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 4.  Cholangiocarcinoma and its management.

Authors:  S A Khan; A Miras; M Pelling; S D Taylor-Robinson
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

Review 5.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

6.  Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings.

Authors:  Nobuhiro Fujita; Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Huanlin Wang; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

7.  A new peroral mother-baby endoscope system for biliary tract disorders.

Authors:  Christian Prinz; Andreas Weber; Stefanie Goecke; Bruno Neu; Alexander Meining; Eckart Frimberger
Journal:  World J Gastrointest Endosc       Date:  2014-01-16

8.  Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis.

Authors:  Fei Zhong; Shineng Zhang; Chunkui Shao; Jing Yang; Xiangyuan Wu
Journal:  Pathol Oncol Res       Date:  2009-12-12       Impact factor: 3.201

9.  Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.

Authors:  M Sinn; A Nicolaou; B Gebauer; P Podrabsky; D Seehofer; J Ricke; B Dörken; H Riess; B Hildebrandt
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

10.  [Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].

Authors:  M Fuchs; W Schepp
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.